Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study

Future Oncology, Ahead of Print.

Source: Future Oncology - December 21, 2023 Category: Cancer & Oncology Authors: Simon Chowdhury Anders Bjartell Neeraj Agarwal Byung H Chung Robert W Given Andrea J Pereira de Santana Gomes Axel S Merseburger Mustafa Özgüroğlu Álvaro Juárez Soto Hirotsugu Uemura Ding-Wei Ye Sabine D Brookman-May Anil Londhe Amitabha Bhaumik Sune Source Type: research